[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"vision-impairment-and-blindness\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:vision-impairment-and-blindness":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,46,71],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":17,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100594099","developing-and-testing-a-model-to-identify-preventive-vision-loss-among-older-patients-in-general-practice-100594099",false,"NCT07015034","Developing and Testing a Model to Identify Preventive Vision Loss Among Older Patients in General Practice","Developing and Testing a Model to Identify Preventive Vision Loss Among Older Patients in General Practice (DETECT)","DETECT","Inclusion Criteria:\n\n* +70 years\n* One or more chronic diseases\n* Are followed by GP du to chronic disease\n\nExclusion Criteria:\n\n* Dementia diagnosis\n* Known eye-diseases or are currently followed by private ophtalmologist\n* Not able to understand Danish",true,"ALL","70 Years",{"count":21,"type":22},460,"ESTIMATED","INTERVENTIONAL",[25],"NA","In this cohort study, the investigators will test vision screenings in Danish general practice for patients over 70 years of age with minimum one chronic condition. The main outcome is detection of vision impairment and secondary outcome is detection of conditions needing ophthalmologic follow-up but not presenting vision impairment at present time.",[28,29,30,31,32],"Vision Impairment and Blindness","Glaucoma","Age-Related Macular Degeneration","Cataract","Diabetic Retinopathy","RECRUITING","2026-04-23",{"date":36,"type":37},"2026-04-29","ACTUAL",{"date":39,"type":37},"2024-05-15",{"date":41,"type":22},"2027-07-15",{"name":43,"class":44},"University of Copenhagen","OTHER",2,{"id":47,"slug":48,"hasResults":11,"nctId":49,"briefTitle":50,"officialTitle":51,"acronym":4,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":18,"minAge":53,"maxAge":19,"enrollmentInfo":54,"targetDuration":4,"studyType":23,"phases":56,"briefSummary":57,"conditions":58,"keywords":4,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":64,"completionDateStruct":66,"leadSponsor":68,"locationsCount":70},"100625675","multicenter-study-of-transcranial-magnetic-stimulation-on-vision-restoration-100625675","NCT07425717","Multicenter Study of Transcranial Magnetic Stimulation on Vision Restoration","Effectiveness of TMS for Visual Restoration: a Multicenter Randomized Controlled Trial","Inclusion Criteria:\n\n* between 45 and 70 years old\n* bilateral severe MMD (META-PM grades ≥ 3)\n* no prior TMS history or contraindications to TMS\n\nExclusion Criteria:\n\n* other significant ocular diseases, such as refractive media opacity, glaucoma, uveitis, ocular trauma, untreated retinal detachment, or lens dislocation\n* received anti-vascular endothelial growth factor treatment or other ocular surgeries within 3 months\n* history of epilepsy or family history of epilepsy, intracranial metal implants, or severe cerebrovascular diseases\n* mental illness, cognitive impairment (MMSE score \\\u003C 24), unable to communicate effectively\n* severe heart disease, liver or kidney dysfunction, or coagulation disorders\n* pregnant or lactating women\n* currently participating in other clinical trials.","45 Years",{"count":55,"type":22},136,[25],"The goal of this clinical trial is to learn if transcranial magnetic stimulation (TMS) works to restore vision in adults with severe retinal degeneration. It will also learn about the safety of TMS treatment. The main questions it aims to answer are:\n\n1. Does TMS treatment improve the visual function of participants?\n2. What medical problems do participants have when receiving TMS treatment? Researchers will compare TMS treatment to a sham stimulation (identical procedures using a sham coil without effective magnetic field output) to see if TMS treatment works to restore their vision.\n\nParticipants will:\n\nUndergoTMS treatment to a sham stimulation for consecutive 5 days Visit the clinic at 5 days, 4 weeks, 3 months, 6 months, 12 months after start of the treatment for checkups and tests",[59,28],"Retinal Degeneration","NOT_YET_RECRUITING","2026-02-20",{"date":63,"type":37},"2026-02-23",{"date":65,"type":22},"2026-06-01",{"date":67,"type":22},"2029-05-31",{"name":69,"class":44},"Shanghai High Myopia Study Group",4,{"id":72,"slug":73,"hasResults":11,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":17,"sex":18,"minAge":78,"maxAge":79,"enrollmentInfo":80,"targetDuration":4,"studyType":82,"phases":4,"briefSummary":83,"conditions":84,"keywords":86,"overallStatus":60,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":4},"100429681","vision-improvement-for-legally-blind-dry-amd-patients-100429681","NCT04875234","Vision Improvement for Legally Blind Dry AMD Patients","Vision Improvement for Legally Blind Dry Age-Related Macular Degeneration Patients","IInclusion Criteria:\n\n* Male or Female\n* Any race\n* Patient is at least 50 years old.\n* Patient must have dry AMD in the study eye.\n* Patient is legally blind due to AMD - i.e., has corrected distance visual acuity (CDVA) of 20\u002F125 or worse (45 letters; logMAR ≥ 0.80) in the study eye.\n* Patient has normal corneal surface topography on videokeratography (i.e., without distorted or unclear corneal mires).\n* Patient is not a contact lens wearer.\n* Patient is willing and able to comply with all examinations.\n* Patient must be competent to sign an informed consent form before study entry.\n\nExclusion Criteria:\n\n* Visually significant cataract in the study eye\n* Presence of a visually significant posterior capsule opacity if prior cataract surgery has been performed in the study eye\n* Any visually significant disease process in any ocular structure other than AMD that would affect vision in the study eye\n* Previous corneal surgery in the study eye\n* Presence or history of any other condition or finding that, in the opinion of the investigator, makes the patient unsuitable as a candidate for study participation or may confound the outcome of the study","50 Years","100 Years",{"count":81,"type":22},40,"OBSERVATIONAL","This retrospective observational study is intended to assess the feasibility of using a nonsignificant risk device for vision improvement for legally blind dry AMD patients.",[85,28],"Dry Age-related Macular Degeneration",[87],"AMD, vision impairment, blindness","2023-03-21",{"date":90,"type":37},"2023-03-22",{"date":92,"type":22},"2024-01",{"date":94,"type":22},"2026-12",{"name":96,"class":97},"Optimal Acuity Corporation","INDUSTRY"]